Fig. 2

Bufalin suppresses TME-mediated angiogenesis by inhibiting angiogenic factors. Relative PDGFA, VEGF, E-selectin and P-selectin mRNA expression in HUVECs after treatment with CT26-CM (a), CAF-CM (b) or TMA-CM (c) with or without bufalin (BU). d–f WB showing the protein expression of VEGF, p-STAT3 and STAT3 in HUVECs treated with different TME-CMs in the presence or absence of BU, with total β-actin as a control. g–i The concentration of VEGFA in HUVECs supernatant after treatment with different TME-CMs in the presence or absence of BU. j Immunofluorescence analysis showing p-STAT3⁺ HUVECs after treatment with different TME-CMs in the presence or absence of BU. *P < 0.05, **P < 0.01, ***P < 0.001. Data are shown as mean s.e.m. BU, bufalin